Celebrity will sail the Danube and Rhine in its first season of river cruising
Celebrity River Cruises will cruise the Rhine and Danube in its first season in 2027.
The brand, an offshoot of ocean line Celebrity Cruises, announced plans earlier this year to expand into river cruising with an initial order of 10 ships. The design of the ships will be inspired by the Edge-class ocean ships and operate with an all-inclusive model. Alcoholic drinks, WiFi and one excursion per port will be included in the fare, a Celebrity spokesperson confirmed to Travel Weekly.
The river cruise line said it will unveil itinerary details and open bookings this summer.
The Rhine and Danube are Europe's two most popular waterways for river cruises. The Rhine alone carries about a quarter of river cruise passengers each year, making it the most popular, followed by the Danube, according to Cleveland Research Company.
Royal Caribbean Group CEO Jason Liberty said during the company's Q4 earnings call in late January that expansion into river cruising "is not a hobby for us."
"We are taking this extremely seriously, and we want to make sure we can live up to delivering the best vacation experiences in the world and make sure we're doing so in a responsible way," Liberty said.
Liberty indicated that about half of Royal Caribbean Group's guests have experienced or intend to take a river cruise.
Travel advisors have said that Celebrity's loyal customer base and brand recognition could lure a younger crowd.
Celebrity is just one well-known brand wading into river cruising. Lindblad Expeditions has partnered with Transcend Cruises to sail the Rhine, and tour operator Trafalgar will offer Danube and Rhine itineraries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
ASCO: new Sarclisa data support subcutaneous administration with on-body injector Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion. Alyssa Johnsen, MD, PhD Global Therapeutic Area Head, Immunology and Oncology Development 'Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation thatcouldimprove and streamline the treatment process for both patients and providers. We are pleased to share thesedata, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forwardtopotentiallybringing this formulation and administrationoptionto the multiple myeloma community.' The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection. The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections' enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort. The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any regulatory authority. IRAKLIA phase 3 study IRAKLIA is a global, randomized, open-label, pivotal phase 3 non-inferiority study comparing Sarclisa SC administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone (Pd) in adult patients with R/R MM who have received at least one prior line of treatment. At the data cut-off of November 6, 2024, and a median follow-up of 12 months, the study demonstrated: Primary endpoints Secondary endpoints The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a notably lower rate of systemic IRs. No new safety concerns were observed, except for low-grade local injection site reactions (ISRs) associated with SC administration that occurred with a low incidence (0.4%, n=19/5,145 injections). Nearly all ISRs were grade 1, except for one episode of grade 2. Xavier Leleu, MD, PhD Head of the Department of Hematology and Myeloma Clinic at the Hôpital La Mileterie and study investigator 'Results from the IRAKLIA phase 3 study represent a potentially transformational advancement in the administration of multiple myeloma treatment. These data not only establish non-inferiority between Sarclisa administered both subcutaneously and intravenously across several key endpoints but reinforce the positive impact that this on-body injector could have on the patient treatment experience, as demonstrated by patient satisfaction scores.' In addition to the oral presentation at ASCO, the full data were simultaneously published in the Journal of Clinical Oncology. IZALCO phase 2 study In addition to the IRAKLIA phase 3 study, Sanofi also presented new data from the randomized, sequential, open-label, IZALCO phase 2 study evaluating the efficacy and safety of Sarclisa SC administered via manual push or an OBI, in combination with carfilzomib and dexamethasone (Kd) in adult patients with R/R MM who have received one to three prior lines of therapy. At a median follow-up of 10.1 months, the study demonstrated: The overall safety profile of Sarclisa SC-Kd observed in this study was consistent with the established safety profile of Sarclisa IV-Kd, with no new safety concerns observed. Advancing patient and provider-centric innovation in MM While SC administration is currently available for certain MM treatment regimens through a manual injection, administering large-volume medicines manually can present significant challenges, including a labor-intensive process for nurses, risk of strain and needlestick injuries, and potential need for larger needles that may compromise patient comfort and increase anxiety. Mehul Desai, PharmD, MBA Vice President, Medical Affairs, Enable Injections 'We believe multiple myeloma patients deserve a more convenient and comfortable treatment experience and recognize the crucial role providers play in delivering that care. Through our collaboration with Sanofi, we've aspired to advance an on-body injector that could transform the treatment experience for patients and providers alike. The results from the IRAKLIA and IZALCO studies represent a significant step toward our ambition and validate the potential of the on-body injector to deliver the same high standard of efficacy established with intravenous Sarclisa.' In addition to IRAKLIA and IZALCO, Sanofi is also evaluating Sarclisa SC administration via an OBI in the front-line treatment setting. The ISASOCUT phase 2 study conducted by the University of Poitiers, is evaluating Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) in adult patients with newly diagnosed MM (NDMM) not eligible for autologous stem-cell transplant (ASCT), while the German-speaking Myeloma Multicenter Group (GMMG)-HD8 phase 3 study, conducted in collaboration with the GMMG and the German Multiple Myeloma Study Group Consortium (DSMM), is evaluating Sarclisa SC-VRd induction in NDMM patients who are eligible for ASCT. In addition, results from the IZALCO, IRAKLIA and ISASOCUT studies will be presented at the European Hematology Association Congress later this month. The IRAKLIA abstract was also hand-selected to be included in the 2025 Best of ASCO program, held later in the summer of 2025, following the ASCO Annual Meeting. The data from these studies, collectively, will form the basis for global regulatory submissions. Sarclisa administered subcutaneously via the on-body injector or manual administration is investigational and has not been approved for any use by any regulatory authority. The safety and efficacy of this formulation and delivery method have not been established. About the IRAKLIA and IZALCO studies IRAKLIA is a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of Sarclisa SC formulation administered at a fixed dose SC via an OBI versus weight-based dosed Sarclisa IV in combination with Pd in adult patients with R/R MM who have received at least one prior line of therapy. The co-primary outcomes being assessed are ORR, defined as the proportion of patients with stringent CR, CR, VGPR, and partial response (PR) according to the 2016 IMWG criteria assessed by Independent Review Committee (IRC), and observed C trough at steady state (pre-dose at C6D1), defined as observed Sarclisa plasma concentrations. IZALCO is a two-part, randomized, sequential, open-label, phase 2 study evaluating the efficacy and safety of Sarclisa SC formulation administered SC via manual push or an OBI in adult patients with R/R MM who have received one to three prior lines of therapy. The primary objective is ORR, as assessed by IRC. The secondary objective is patient preference for the OBI versus manual administration of Sarclisa SC. About Enable Injections Based in the US (Cincinnati, OH), Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse. enFuse is an innovative wearable drug delivery platform that is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit About Sarclisa Sarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, UK, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media Relations Sandrine Guendoul | +33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Léo Le Bourhis | +33 6 75 06 43 81 | [email protected] Victor Rouault | +33 6 70 93 71 40 | [email protected] Timothy Gilbert | +1 516 521 2929 | [email protected] Investor Relations Thomas Kudsk Larsen |+44 7545 513 693 | [email protected] Alizé Kaisserian | +33 6 47 04 12 11 | [email protected] Felix Lauscher | +1 908 612 7239 | [email protected] Keita Browne | +1 781 249 1766 | [email protected] Nathalie Pham | +33 7 85 93 30 17 | [email protected] Tarik Elgoutni | +1 617 710 3587 | [email protected] Thibaud Châtelet | +33 6 80 80 89 90 | [email protected] Yun Li | +33 6 84 00 90 72 | [email protected] Sanofi forward-looking statements All trademarks mentioned in this press release are the property of the Sanofi group with the exception of enFuse. Attachment
Yahoo
3 hours ago
- Yahoo
Royal Caribbean shares surprising news on smaller ships
Royal Caribbean shares surprising news on smaller ships originally appeared on Come Cruise With Me. Royal Caribbean has been talking about smaller ships for a very long time. It seems that every time the cruise line launches a new Icon or Oasis-class ship its executives get hit with multiple questions about when they will build smaller ships. In recent years, the cruise line has not exactly done to these questions. Royal Caribbean Group CEO Jason Liberty and Royal Caribbean Group CEO Michael Bayley have openly admitted that a smaller class has been talked man, however, has given out much information. Passengers want new, smaller ships because these ships can stop in ports where the larger ships do not fit. Some cruise line passengers also preferred the intimacy of a few people being onboard. Some of Royal Caribbean's smaller ships are also near the end of their lifetime. All ships get repurposed and refurbed all the time, 35 years is considered a reasonable lifetime. Now, the cruise line has quietly given out some information on its plans for smaller Caribbean has been talking about the need for a new class of smaller ships for quite some time. "We're always designing the next classes of ships really for all of our brands," Liberty said during Royal Caribbean's second-quarter-earnings call. "We specifically pick segments and brands in those segments and deployments and experiences that we believe have a very long runway to generate demand globally, as each of our brands are globally sourced business." He also made it clear that the cruise line sees a need. "And, of course, the other thing I think that's important when you think about ship classes, whether they could be small, they could be larger, is kind of also a consideration that we also have ships that are reaching 30, 35 years. And so some of this is not just about we want to build same-size ships, smaller ships. It's also replacing ships that will eventually kind of reach their end of life." At the time of those comments, Liberty was just talking. The cruise line had not ordered a new class of ships or fully confirmed that one was coming. Royal Caribbean's Senior Vice President of Sales and Trade Support Vicki Freed commented on smaller ships during a recent sailing of Ovation of the was speaking to a group of travel advisors (or travel agents depending upon the lingo) and she confirmed the new class of ships. "The Discovery Project is our next new class of ships, following the Icon of the Seas, and the Star of the Seas, and the Legend the Seas. And we're in the design process now," she said, according to Royal Caribbean Blog. "We meet on a regular basis with the architects, with the ops team and the hotel operations, food and beverage. And so it is a top secret design at this point." Freed also made some remarks that suggest that the project has moved forward internally. "It's an exciting project. It'll be a new class of ship. In true Royal Caribbean style, it will be special, it will be innovative. And I think it'll be something that'll be a home run from the beginning," she Caribbean has two classes of smaller ships, Radiance and Vision classes. The newest of these ships, Jewel of the Seas, was built in 2004. The cruise line's oldest ship, Grandeur of the Seas, first sailed in Dec. 1996. At max capacity, Grandeur holds roughly 2,400 passengers while Icon of the Seas, the world's largest cruise ship, can hold 7,600. (The Arena Group will earn a commission if you book a cruise.) , or email Amy Post at or call or text her at 386-383-2472. This story was originally reported by Come Cruise With Me on Jun 2, 2025, where it first appeared.
Associated Press
3 hours ago
- Associated Press
UK government ready to take Abramovich to court over Chelsea sale proceeds for Ukraine
Three years after Russian billionaire Roman Abramovich was forced to sell Premier League club Chelsea, the British government said on Tuesday it was prepared to go to court to ensure the proceeds reached war victims in Ukraine. Abramovich was sanctioned in the wake of Russia's invasion of Ukraine in 2022 and sold two-time Champions League winner Chelsea to a consortium fronted by Americans Todd Boehly and Clearlake Capital for 2.5 billion pounds ($3.2 billion) in May of that year. Abramovich said before the sale that net proceeds would go to a charitable foundation 'for the benefit of all victims of the war in Ukraine.' But the money remained frozen in a bank and the British government said it was still to make its way to those in need. A joint statement by Treasury chief Rachel Reeves and Foreign Secretary David Lammy said the government was ready to mount legal action. 'The government is determined to see the proceeds from the sale of Chelsea Football Club reach humanitarian causes in Ukraine, following Russia's illegal full-scale invasion. We are deeply frustrated that it has not been possible to reach agreement on this with Mr Abramovich so far,' they said. 'While the door for negotiations will remain open, we are fully prepared to pursue this through the courts if required, to ensure people suffering in Ukraine can benefit from these proceeds as soon as possible.' Abramovich was sanctioned when the British government targeted what then-Foreign Secretary Liz Truss described as 'oligarchs and kleptocrats' with close links to Russian President Vladimir Putin and 'complicit in his aggression.' The funds from the sale, however, still belong to Abramovich even though they are frozen. They cannot be used or moved without the issue of a licence from the Office of Financial Sanctions Implementation. The government insists they must be used for humanitarian purposes in Ukraine. ___ James Robson is at ___ AP soccer:
